Perle (PRL) 24-hour amplitude 516.7%: Binance exclusive TGE, driven by listing on Coinbase and KuCoin
Bitget Pulse2026/03/25 23:05Volatility Overview
In the past 24 hours, PRL’s price surged from a low of $0.03 to a high of $0.185, now trading at $0.15298, with a price swing of 516.7%. 24-hour trading volume increased significantly, with CoinMarketCap data showing approximately $60.79 million, and CoinGecko about $3.13 million, reflecting high liquidity anomalies.
Analysis of Abnormal Movement Causes
- Binance Wallet Exclusive TGE: On March 25, Binance Wallet launched Perle Labs (PRL) as its 45th exclusive token generation event, limited to Alpha Points holders. This sparked a closed capital cycle and listing expectations, driving a price pump.
- Multiple Exchanges Launching Spot Trading: Coinbase announced the launch of PRL-USD spot trading on March 25; KuCoin simultaneously enabled SOL-SPL network deposits and auction trading, directly boosting circulation and liquidity.
Market Opinions and Outlook
The mainstream community sentiment is positive, with discussions on X platform focusing on PRL tokenomics (10B fixed supply, 37.5% community allocation, team/investors with 12-month lock-up + 36-month linear vesting), viewing it as a long-term value anchor for AI data infrastructure to mitigate early sell pressure. Analysts are optimistic about network effects post-listing but warn of high volatility risks, suggesting attention to follow-up unlocking and enterprise adoption.
Note: This analysis is auto-generated by AI based on public data and on-chain monitoring, for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
